Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2021-06-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
深圳信立泰药业股份有限公司非公开发行股票发行情况报告书暨上市公告书（摘要）
Capital/Financing Update Classification · 95% confidence The document is titled "发行情况报告书暨上市公告书摘要" which translates to "Issuance Report and Listing Announcement Summary." It details a non-public issuance of shares by Shenzhen Salubris Pharmaceuticals Co., Ltd., including the number of shares issued, pricing, subscription details, investor lists, regulatory approvals, and lock-up periods. The content focuses on the issuance process, subscription, and listing of new shares, which is characteristic of a capital raising or financing update. There is no indication that this is an annual report, earnings release, or other types of filings. The document is comprehensive and not a mere announcement of a report, so it is not a Report Publication Announcement (RPA). The detailed description of the issuance and listing of new shares fits the definition of a Capital/Financing Update (CAP).
2021-06-21 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司非公开发行股票之发行过程和认购对象合规性的报告
Capital/Financing Update Classification · 100% confidence The document is a detailed report from 华英证券有限责任公司 (Huaying Securities Co., Ltd.) regarding the compliance of the issuance process and the subscription objects for a non-public stock issuance by 深圳信立泰药业股份有限公司 (Shenzhen Salubris Pharmaceuticals Co., Ltd.). It includes extensive information about the issuance price, number of shares, subscription objects, approval procedures, subscription invitations, subscription prices, allocation results, payment and verification, and legal compliance. The document is not an announcement or a brief summary but a comprehensive compliance report related to a capital raising event. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (11,775 characters) and content confirm it is a full report rather than a mere announcement or certification. Therefore, the appropriate classification is CAP.
2021-06-21 Chinese
关于控股股东部分股份质押及解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge and release of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, released, and the current status of pledged shares. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about share pledging activities, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short and it is an announcement rather than a report or detailed financial statement.
2021-06-18 Chinese
关于注射用头孢呋辛钠通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (injection cefuroxime sodium) passing a consistency evaluation by the National Medical Products Administration. It includes regulatory references, product details, and potential market impact. The document is short (1015 characters) and serves as a formal announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or shareholder voting results. It is not an annual or interim report, nor a call transcript or capital update. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval and market implications without fitting other specific categories.
2021-06-17 Chinese
关于第二期员工持股计划完成非交易过户暨回购股份处理完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the completion of non-trading transfer of shares for the second employee stock ownership plan and the completion of share repurchase processing. It details the source and quantity of shares, subscription and transfer status, related party relationships, and accounting treatment of the employee stock ownership plan. The document is a formal announcement about the progress and completion of a specific employee stock ownership plan and share repurchase, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather regulatory disclosures about share transactions and employee stock plans. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks and share issuance related to employee stock plans.
2021-06-15 Chinese
第五届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details decisions made by the board regarding the transfer of equity by a wholly-owned subsidiary and the proposal to convene an extraordinary general meeting. The document includes meeting attendance, voting results, and references to further shareholder meetings and disclosures. It does not contain financial statements, audit opinions, or detailed financial data. It is not a report itself but an announcement of board decisions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, confirming this classification.
2021-06-14 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.